Literature DB >> 28855211

The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells.

Goodwin G Jinesh1, Ashish M Kamat1.   

Abstract

Genomic instability and immune evasion are hallmarks of cancer. Apoptotic cancer stem cells can evade cell death by undergoing cellular transformation by constructing "blebbishields" from apoptotic bodies. In this study, we report a novel linkage between genomic instability and phagocytosis evasion that is coordinated by the blebbishield emergency program. Blebbishield emergency program evaded genomic instability checkpoint, expressed genomic instability-associated genes at distinct phases of cellular transformation, exhibited chromosomal instability, and promoted increase in nuclear size. Blebbishields fused with immune cells to evade phagocytosis, and the resultant hybrid cells exhibited increased migration, tumorigenesis, metastasis, red blood cell recruitment to tumors, and induced hepatosplenomegaly with signatures of genomic instability, blebbishield emergency program, and phagocytosis evasion to offer poor prognosis. Overall, our data demonstrate that the blebbishield emergency program drives evasion of chromosomal instability and phagocytosis checkpoints by apoptotic cancer stem cells. Cancer Res; 77(22); 6144-56. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28855211     DOI: 10.1158/0008-5472.CAN-17-0522

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Bladder cancer: Shields up, red alert: the blebbishield emergency programme.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2017-09-19       Impact factor: 14.432

2.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

Review 3.  Targeting K-Ras and apoptosis-driven cellular transformation in cancer.

Authors:  Isha Godwin; Nikhil Ponnoor Anto; Smitha V Bava; Mani Shankar Babu; Goodwin G Jinesh
Journal:  Cell Death Discov       Date:  2021-04-14

Review 4.  Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis.

Authors:  Goodwin G Jinesh; Andrew S Brohl
Journal:  Signal Transduct Target Ther       Date:  2022-08-23

5.  Fractionated irradiation of MCF7 breast cancer cells rewires a gene regulatory circuit towards a treatment-resistant stemness phenotype.

Authors:  Auchi Inalegwu; Bart Cuypers; Jürgen Claesen; Ann Janssen; Amelie Coolkens; Sarah Baatout; Kris Laukens; Winnok H De Vos; Roel Quintens
Journal:  Mol Oncol       Date:  2022-06-15       Impact factor: 7.449

6.  Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Marian T Smallin; Andrew Davis; Hayley D Ackerman; Payal Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.996

Review 7.  Molecular genetics and cellular events of K-Ras-driven tumorigenesis.

Authors:  G G Jinesh; V Sambandam; S Vijayaraghavan; K Balaji; S Mukherjee
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

8.  Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma.

Authors:  Goodwin G Jinesh; Marco Napoli; Hayley D Ackerman; Payal M Raulji; Nicole Montey; Elsa R Flores; Andrew S Brohl
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.996

9.  Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers.

Authors:  Goodwin G Jinesh; Elsa R Flores; Andrew S Brohl
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.